SU437512A1 - Лечебный препарат - Google Patents

Лечебный препарат

Info

Publication number
SU437512A1
SU437512A1 SU1174003A SU1174003A SU437512A1 SU 437512 A1 SU437512 A1 SU 437512A1 SU 1174003 A SU1174003 A SU 1174003A SU 1174003 A SU1174003 A SU 1174003A SU 437512 A1 SU437512 A1 SU 437512A1
Authority
SU
USSR - Soviet Union
Prior art keywords
therapeutic drug
effect
tablets
psychotropic
therapeutic
Prior art date
Application number
SU1174003A
Other languages
English (en)
Inventor
Михаил Давидович Машковский
Владимир Генрихович Яшунский
Роальд Абрамович Альтшулер
Original Assignee
Всесоюзный научно-исследовательский химико-фармацевтический институт им. Серго Орджоникидзе
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Всесоюзный научно-исследовательский химико-фармацевтический институт им. Серго Орджоникидзе filed Critical Всесоюзный научно-исследовательский химико-фармацевтический институт им. Серго Орджоникидзе
Priority to SU1174003A priority Critical patent/SU437512A1/ru
Priority to DE19681770857 priority patent/DE1770857A1/de
Priority to FR159469A priority patent/FR8171M/fr
Priority to GB34001/68A priority patent/GB1242742A/en
Application granted granted Critical
Publication of SU437512A1 publication Critical patent/SU437512A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

1
Известно использование -различных лечебных иренаратов в качестве психотропных средств.
Предлагаетс  в качестве психотропного средства использовать хлоргидрат З-р-фелилГкюнропи .г-снднонимйн (сид/аофен).
Сиднофс оказывает сти.мулирующее .вли ние на дбнтральную nepBiHyio систему. О,н вызывает у животных ха-рактериые -изменеки  поведенческих реакций, усиливает 1рефле(Кто .р-ную возбудимость, и.реп тствует 1разв итию седативного и гииотекзивного действи  резерпина и т. п. Сидиофеи усиливает действие на цб)1тралы1ую «epBiHyio систему биогенных аминов и обладает способностью обратимо и конкурентио угнетать активность моноами ноксидазы .
Г{риме;и 1От сиднофен в виде таблеток, содержащих по 5 мг пренарата, 2-3 раза в
дань по 1-2 таблетки. По срав-неиию с и-ндопаном л фанамииом сиднофен оказывает
менее резкое и более длительное действие.
Пред.мет изобретени 
Пр им€1Н eiH ие х лс р гидр а т а 3- р - ф е л и зон р о пи л - сиди о,н им ил а (.сиднофен а) в качестве исиX о тр о и н о го средств ;i.
SU1174003A 1967-07-19 1967-07-19 Лечебный препарат SU437512A1 (ru)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SU1174003A SU437512A1 (ru) 1967-07-19 1967-07-19 Лечебный препарат
DE19681770857 DE1770857A1 (de) 1967-07-19 1968-07-11 Arzneimittel zur stimulierenden Wirkung auf das Zentralnervensystem und das Verfahren zur Herstellung des Wirkstoffs dieses Mittels
FR159469A FR8171M (ru) 1967-07-19 1968-07-17
GB34001/68A GB1242742A (en) 1967-07-19 1968-07-17 Drug for stimulating the central nervous system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU1174003A SU437512A1 (ru) 1967-07-19 1967-07-19 Лечебный препарат

Publications (1)

Publication Number Publication Date
SU437512A1 true SU437512A1 (ru) 1974-07-30

Family

ID=20440935

Family Applications (1)

Application Number Title Priority Date Filing Date
SU1174003A SU437512A1 (ru) 1967-07-19 1967-07-19 Лечебный препарат

Country Status (4)

Country Link
DE (1) DE1770857A1 (ru)
FR (1) FR8171M (ru)
GB (1) GB1242742A (ru)
SU (1) SU437512A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324897A (en) * 1980-10-02 1982-04-13 American Home Products Corporation 1,2,3 Oxadiazolium salts
DE3522191A1 (de) * 1985-06-21 1987-01-15 Cassella Ag Photostabilisierung von sydnoniminen

Also Published As

Publication number Publication date
GB1242742A (en) 1971-08-11
FR8171M (ru) 1970-08-31
DE1770857A1 (de) 1972-01-13

Similar Documents

Publication Publication Date Title
Atsmon et al. Further studies with propranolol in psychotic patients: Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion
Tapia Children who are cruel to animals
Frank Sanity+ survival: Psychological aspects of war and peace.
Chase et al. Hypothalamic releasing factors and Parkinson disease
Park et al. Toxic effects of tear gas on an infant following prolonged exposure
SU437512A1 (ru) Лечебный препарат
Masserman Neurosis and alcohol: An experimental study
Smith et al. Glucagon for propranolol overdose
Elizur et al. The clinical and psychological effects of pemoline in depressed patients—a controlled study
Kamerling et al. Naloxone‐induced abdominal distress in the horse
Cathers et al. Acute ibuprofen toxicosis in a ferret
US2939816A (en) Insect deterrents containing staphisagria
SU329890A1 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВОВСЕСОЮт^лт^НТНО-Т^;&ИЗЛХО
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
Brachet Observations on the Use of Crystallized Subacetate of Lead in Hypertrophy of the Heart
SU449724A1 (ru) Отхаркивающее средство "мукалтин'
SU552085A1 (ru) Средство дл лечени нарушений свертывающей системы крови при тромбоцитопенических состо ни х различного происхождени и дл стимул ции гемоопоэза "эритрофосфатид"
Houston et al. Keratoconjunctivitis sicca in the dog following prolonged use of salazopyrin and other 5-ASA containing drugs for treatment of canine colitis
Salva Anabolic steroids and sports
Waugh SELECTIVE ABSORPTION BY THE CELL
Washington ART. IX. Observations on Yellow Fever. Read before the Medical Society of the District of Columbia.
dANSSEN PHARMACEUTICAL lmodium
Isaacson et al. The hypothalamus
Lyubimov et al. On the mechanism of lithium salts action upon the rats' predilection for ethanol.
Lake-Bakaar Clinical Discussions: An Overview